Biotech | March 01, 2022
Novavax UK Phase 3 trial demonstrates protection from Covid-19 over six-month period
High level of vaccine efficacy maintained over a 6-month period of surveillance
High level of vaccine efficacy maintained over a 6-month period of surveillance
Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
It is the first approved blood test that can predict likely progression to Alzheimer's Disease up to six years in advance
Clinical trial supply company strengthens its presence in the European Union
These results are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
N Yuvraj, Joint Secretary, Dept of Pharmaceuticals, Satish Reddy, Chairman, Dr Reddy’s Laboratories; Kiran Mazumdar Shaw, Executive Chairperson, Biocon Group; Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines and Shravil Patel, MD, Zydus Lifesciences discuss the way forward for the India pharma industry
Tamper evident caps with incorporated RFID technology offer a significant reduction in RFID implementation costs
Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases
The joint initiative is called J-ARC Healthcare Solutions
Subscribe To Our Newsletter & Stay Updated
